These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12026400)

  • 41. Burkholderia cepacia and cystic fibrosis--50 years on.
    Moore JE; Elborn JS
    Commun Dis Public Health; 2001 Jun; 4(2):114-6. PubMed ID: 11524998
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of contamination of the dentist and dental surgery environment with Burkholderia (Pseudomonas) cepacia during treatment of children with cystic fibrosis.
    Pankhurst CL; Harrison VE; Philpott-Howard J
    Int J Paediatr Dent; 1995 Dec; 5(4):243-7. PubMed ID: 8957838
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center.
    Kennedy MP; Coakley RD; Donaldson SH; Aris RM; Hohneker K; Wedd JP; Knowles MR; Gilligan PH; Yankaskas JR
    J Cyst Fibros; 2007 Jul; 6(4):267-73. PubMed ID: 17137846
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy?
    Ensor E; Humphreys H; Peckham D; Webster C; Knox AJ
    J Hosp Infect; 1996 Jan; 32(1):9-15. PubMed ID: 8904368
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outbreak of Burkholderia cepacia bacteremia in immunocompetent children caused by contaminated nebulized sulbutamol in Saudi Arabia.
    Ghazal SS; Al-Mudaimeegh K; Al Fakihi EM; Asery AT
    Am J Infect Control; 2006 Aug; 34(6):394-8. PubMed ID: 16877110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel strategy for the isolation and identification of environmental Burkholderia cepacia complex bacteria.
    Vanlaere E; Coenye T; Samyn E; Van den Plas C; Govan J; De Baets F; De Boeck K; Knoop C; Vandamme P
    FEMS Microbiol Lett; 2005 Aug; 249(2):303-7. PubMed ID: 16000240
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Burkholderia cepacia in cystic fibrosis. Variable disease course.
    Frangolias DD; Mahenthiralingam E; Rae S; Raboud JM; Davidson AG; Wittmann R; Wilcox PG
    Am J Respir Crit Care Med; 1999 Nov; 160(5 Pt 1):1572-7. PubMed ID: 10556123
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Suppurative mediastinitis secondary to Burkholderia cepacia in a patient with cystic fibrosis.
    George RB; Cartier Y; Casson AG; Hernandez P
    Can Respir J; 2006; 13(4):215-8. PubMed ID: 16779467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Burkholderia cepacia from a sink drain.
    Moore JE; Thompson I; Crowe M; Xu J; Shaw A; Millar BC; Redmond AO; Reid AJ; Clarke C; Elborn JS
    J Hosp Infect; 2002 Mar; 50(3):235-7. PubMed ID: 11886206
    [No Abstract]   [Full Text] [Related]  

  • 50. Burkholderia respiratory tract infections in Italian patients with cystic fibrosis: molecular characterization.
    Allice T; Scutera S; Chirillo MG; Savoia D
    J Infect; 2006 Sep; 53(3):159-65. PubMed ID: 16375971
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simultaneous coinfection by multiple strains during Burkholderia cepacia complex infection in cystic fibrosis.
    Yang JH; Spilker T; LiPuma JJ
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):95-8. PubMed ID: 16406186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis.
    Kalish LA; Waltz DA; Dovey M; Potter-Bynoe G; McAdam AJ; Lipuma JJ; Gerard C; Goldmann D
    Am J Respir Crit Care Med; 2006 Feb; 173(4):421-5. PubMed ID: 16272450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Overrepresentation of immunostimulatory CpG motifs in Burkholderia genomes.
    Coenye T; Vandamme P
    J Cyst Fibros; 2005 Sep; 4(3):193-6. PubMed ID: 15963770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas.
    Jones AM; Dodd ME; Webb AK
    Eur Respir J; 2001 Feb; 17(2):295-301. PubMed ID: 11334134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disinfection of Burkholderia cepacia complex from non-touch taps in a neonatal nursery.
    Kotsanas D; Brett J; Kidd TJ; Stuart RL; Korman TM
    J Perinat Med; 2008; 36(3):235-9. PubMed ID: 18576933
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
    Elborn JS; Hodson M; Bertram C
    J Cyst Fibros; 2009 May; 8(3):211-7. PubMed ID: 19372063
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand.
    Kidd TJ; Douglas JM; Bergh HA; Coulter C; Bell SC
    Res Microbiol; 2008 Apr; 159(3):194-9. PubMed ID: 18356026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM; Brown SD
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pseudo outbreak of Burkholderia cepacia in vaginal cultures and intervention by hospital infection control team.
    Serikawa T; Kobayashi S; Tamura T; Uchiyama M; Tsukada H; Takakuwa K; Tanaka K; Ito M
    J Hosp Infect; 2010 Jul; 75(3):242-3. PubMed ID: 20434797
    [No Abstract]   [Full Text] [Related]  

  • 60. Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.
    Govan JR
    J R Soc Med; 2000; 93 Suppl 38(Suppl 38):40-5. PubMed ID: 10911818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.